Compounders Research Compare

Genprex, Inc.(GNPX)

Biotechnology · Austin, TX

$2.66-0.06 (-2.21%)

Delayed quote: Oct 6, 2026, 12:34 PM EDT

About Genprex, Inc.

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Austin, TX

13 employees

www.genprex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ryan Confer

View full financials

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T16:37:16.923Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:37:16.923Z.

Quote observation: 2026-10-06T16:34:43.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,343,127
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 15,154,203
TTM revenue · period ending 2026-06-30: 0

FMP input reference: 325841a12d79c3b22e4488d0564adef7d4bfa7ba78e5cc1d4c3dcb4b1cd6f762

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GNPX EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

GNPX Competitors' EV/Sales Ratio

Genprex, Inc.

Current

Market Cap

$1.34M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.33M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Artelo Biosciences, Inc.

Market Cap

$1.39M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INVO Fertility, Inc.

Market Cap

$1.44M

EV/Sales Ratio

0.22x

TTM Avg

0.55x

3Y Avg

1.65x

5Y Avg

4.41x

NEXGEL, Inc.

Market Cap

$1.44M

EV/Sales Ratio

0.70x

TTM Avg

1.00x

3Y Avg

2.40x

5Y Avg

3.38x

Jupiter Neurosciences, Inc.

Market Cap

$1.25M

EV/Sales Ratio

22.77x

TTM Avg

279.56x

3Y Avg

279.56x

5Y Avg

279.56x

PMGC Holdings Inc.

Market Cap

$1.49M

EV/Sales Ratio

N/A

TTM Avg

0.01x

3Y Avg

35696307.79x

5Y Avg

35696307.79x

Lakewood-Amedex Biotherapeutics, Inc.

Market Cap

$1.49M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Curis, Inc.

Market Cap

$1.49M

EV/Sales Ratio

N/A

TTM Avg

0.94x

3Y Avg

2.21x

5Y Avg

9.57x

Propanc Biopharma, Inc.

Market Cap

$1.18M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Genprex, Inc. (GNPX)	$1.34M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.33M	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.39M	N/A	N/A	N/A	N/A
INVO Fertility, Inc. (IVF)vs ›	$1.44M	0.22x	0.55x	1.65x	4.41x
NEXGEL, Inc. (NXGL)vs ›	$1.44M	0.70x	1.00x	2.40x	3.38x
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.25M	22.77x	279.56x	279.56x	279.56x
PMGC Holdings Inc. (ELAB)vs ›	$1.49M	N/A	0.01x	35696307.79x	35696307.79x
Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs ›	$1.49M	N/A	N/A	N/A	N/A
Curis, Inc. (CRIS)vs ›	$1.49M	N/A	0.94x	2.21x	9.57x
Propanc Biopharma, Inc. (PPCB)vs ›	$1.18M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics